-- Sanofi is on track with plans to spin-off its consumer healthcare business, expected to be valued at about EUR20 billion ($21.70 billion) in a public listing, Financial Times reports, citing sources.
-- Sanofi's consumer division--which includes well-known brands like allergy medicine Allegra and the pain treatments Icy Hot and Aspercreme, accounts for 10% of the French pharmaceutical company's sales--has drawn interest from private equity bidders, according to FT.
-- Goldman Sachs, Morgan Stanley, BNP Paribas, Bank of America and financial group Rothschild & Co. are involved in preparation for the sale and potential float, expected to take place by the end of the year, FT reported.
-- Sanofi didn't immediately respond to a request for comment from Dow Jones Newswires.
Full story: https://on.ft.com/4aKjL66
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
06-03-24 0239ET